Breakthrough SjD Treatment Enters Clinical Trials After RA Success

Rise Therapeutics is expanding its clinical trials to test a new treatment for Sjögren's disease (SjD). The drug, R-2487, has already shown promise in rheumatoid arthritis (RA) and now moves into SjD research. Funding for the study comes from the National Institute of Dental and Craniofacial Research (NIDCR).

Sjögren's disease is a chronic autoimmune condition with no approved therapies targeting its root cause. Patients suffer from immune dysregulation, long-term inflammation, and lymphocytic infiltration of exocrine glands. These symptoms reduce quality of life and raise mortality risks.

R-2487 works differently from standard treatments. Instead of just easing symptoms, it corrects immune dysfunction by restoring long-term immune balance. Early trials in RA revealed a strong safety profile and signs of clinical effectiveness. The drug's mechanism is antigen-independent, meaning it promotes peripheral tolerance without relying on specific immune triggers.

As a first-in-class oral immune modulator, R-2487 aligns with Rise Therapeutics' focus on innovative immunotherapies. The company specialises in Oral Immune Biomodulators for autoimmune diseases and cancer. While details on patient numbers in the RA trial remain undisclosed, the shift to SjD marks a key step in broadening the drug's potential applications.

The clinical evaluation of R-2487 in SjD will assess its ability to address the disease's underlying immune issues. If successful, it could offer the first therapy targeting the cause of SjD rather than just symptoms. The trial's progress will determine whether this approach provides lasting benefits for patients.